Cinfa Biotech GmbH

  • Land: Spanien

Nachricht vom 08.10.2015 | 09:30

Cinfa Biotech initiates biosimilar strategy with pegfilgrastim candidate to treat neutropenia

DGAP-News: Cinfa Biotech, S.L. / Key word(s): Strategic Company Decision

2015-10-08 / 09:30

Press Release

Cinfa Biotech initiates biosimilar strategy with pegfilgrastim candidate to treat neutropenia

Pamplona, Spain - 8 October 2015 - Cinfa Biotech S.L., the biosimilar company of Infarco group, today outlined the Company's strategy to develop and commercialise biosimilar drugs. The Company's first product candidate is B12019, a biosimilar version of Neulasta(R) (pegfilgrastim), starting clinical trials in 2015.

B12019 is a granulocyte colony-stimulating factor (G-CSF) receptor agonist for the treatment of chemotherapy-induced neutropenia. The product candidate has successfully finalised preclinical development and has an agreed clinical development program based upon scientific advice received from the European Medicines Agency (EMA). Furthermore, the manufacturing process (GMP) has been implemented at commercial scale.

Cinfa Biotech was established by Infarco group, Spain, in 2013. A committed investment of initially EUR 70 million underlines Infarco's determination to apply its effective portfolio strategy, as realised by its affiliate company Laboratorios Cinfa as a leading supplier of quality drugs for the European market, now to biosimilars. Cinfa Biotech is creating a pipeline of biosimilars for several indications in oncology and inflammatory diseases to address the growing need for affordable biologics therapies based on proven science, quality, safety and efficacy. Product development, clinical studies, manufacturing and quality control at Cinfa Biotech are conducted in Europe according to the highest European standards.

Dr. Rüdiger Jankowsky, Managing Director of Cinfa Biotech, said: "Cinfa Biotech's pipeline and the development of B12019 is driven by a team of experts in development, manufacturing and commercialization, a team which has already successfully developed and launched biosimilars in different markets throughout the world. Cinfa Biotech will be covering the entire value chain from biosimilar development to commercialization. We are glad to provide patients, physicians, healthcare providers and business partners with affordable treatment options and competitive opportunities based on proven therapies."

Enrique Ordieres, President of Infarco, commented: "The founding of Cinfa Biotech and our investment in a biosimilar pipeline is following the logic of our successful business strategy. As demonstrated with Laboratorios Cinfa, which has become the leading quality supplier for retailing pharmacies in Spain, now present in over 50 countries, there is an urgent medical need to ensure that proven, advantageous and affordable medications are available to all patients. This concept will now be applied to complex and costly biologic drugs. We are committed to improving patient access to healthcare solutions and supporting national healthcare systems through reliable supply of high-quality products. Cinfa Biotech is our answer to this need."

About Infarco - parent company of Cinfa Biotech
Infarco, the parent company of Cinfa Biotech, holds a portfolio of pharmaceutical companies. With 50 years' experience, Infarco represents the successful professional approach of a group of pharmacists to recover the central role of pharmacists in the pharmaceutical industry. The Company today employs over 1,200 people and reinvests an average of 90% of its annual profits in its portfolio companies, thereby driving their development and innovation. Infarco's first subsidiary, Laboratorios Cinfa, has become a successful developer and manufacturer and a recognised leader in the Spanish pharmaceutical market; it is the laboratory with the strongest presence in Spanish homes. As part of the internationalization strategy, the company serves markets in currently over 50 countries and is further expanding.

About Cinfa Biotech
Cinfa Biotech is headquartered in Pamplona, Spain, with offices in Munich, Germany. The company was founded in 2013 and received an initial investment of EUR 70 million from Infarco to create a pipeline of biosimilar drugs to address the growing need for affordable therapies based on proven science, quality, safety and efficacy. A complete team of experts with decades of in-depth experience is developing biosimilars for a range of indications. The commercialisation models will be customised to the needs of partners and markets. Product development, clinical studies, manufacturing and quality control at Cinfa Biotech are conducted in Europe according to the highest European standards.

For Press Enquiries:

MC Services AG
Katja Arnold
Phone: +49 89 210 228-0

Shaun Brown
Phone: +44-20-71485998

2015-10-08 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at and

400717  2015-10-08 

IPO im Fokus


ISIN: DE000A3CM708
Grundkapital (vor IPO): 3.120.000 EUR
Angebotene Aktien: bis zu 690.000 Aktien
Zeichnungsfrist: 11.10.2021 bis voraus. 25.10.2021
Bookbuildingspanne: 3,30 bis 3,60 Euro
Börse: Börse Düsseldorf

Rechtlich maßgeblicher Wertpapierprospekt auf

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“

GBC im Fokus

Börsengang sdm SE: Attraktives Investment

Der Sicherheitsdienstleister sdm SE führt derzeit einen Börsengang am Primärmarkt der Börse Düsseldorf durch. Die Mittel des Börsengangs sollen die Wachstumsstrategie finanzieren und die Ertragskraft deutlich steigern. Im Rahmen unseres DCF-Bewertungsmodells haben wir einen fairen Unternehmenswert (Post Money) zum Ende des Geschäftsjahres 2022 in Höhe von 15,23 Mio. € bzw. 4,09 € je sdm-Aktie ermittelt. Unter einem Preis von 3,50 € pro Aktie sehen wir sdm als ein attraktives Investment und stufen die Aktie mit dem Rating „Kaufen“ ein.

News im Fokus

Vonovia SE: Übernahmeangebot erfolgreich: Vonovia erreicht insgesamt rund 87,6 % der Stimmrechte an der Deutsche Wohnen

26. Oktober 2021, 07:56

Aktueller Webcast


Pressekonferenz – Zwischenmitteilung 9M 2021 - Webcast

28. Oktober 2021

Aktuelle Research-Studie

Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Kaufen Valneva SE

25. Oktober 2021